XML 71 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
Acquisitions - Narrative (Details)
$ in Millions
12 Months Ended
Oct. 19, 2021
USD ($)
Apr. 16, 2021
USD ($)
Nov. 21, 2019
USD ($)
Jul. 15, 2019
USD ($)
Dec. 31, 2021
USD ($)
market
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Business Acquisition [Line Items]              
Estimated fair values of contingent consideration obligations         $ 309 $ 0 $ 0
Goodwill         14,890 14,689 14,703
Cash paid for acquisitions, net of cash acquired         2,529 0 13,617
Acquired in-process research and development         $ 1,505 $ 0 $ 0
Estimated blended statutory rate     20.00%        
Teneobio              
Business Acquisition [Line Items]              
Cash paid $ 994            
Maximum additional consideration due contingent on certain milestones 1,600            
Estimated fair values of contingent consideration obligations 309            
Fair value of liabilities assumed, deferred tax liabilities 253            
Goodwill 251            
Fair value of assets acquired and liabilities assumed, net other assets and liabilities 16            
Teneobio | R & D Technology rights              
Business Acquisition [Line Items]              
Finite-lived Intangible Assets Acquired $ 94            
Weighted average period of amortization 10 years            
Teneobio | Licensing rights              
Business Acquisition [Line Items]              
Finite-lived Intangible Assets Acquired $ 41            
Teneobio | IPR&D              
Business Acquisition [Line Items]              
Acquired in-process research and development 1,054            
Teneobio | IPR&D | AMG 340              
Business Acquisition [Line Items]              
Acquired in-process research and development $ 784            
Five Prime Therapeutics, Inc.              
Business Acquisition [Line Items]              
Cash paid for acquisitions, net of cash acquired   $ 1,600          
Acquired in-process research and development   1,500          
Deferred tax assets   177          
Other liabilities   $ 47          
Otezla              
Business Acquisition [Line Items]              
Cash paid     $ 13,400        
Fair value of liabilities assumed, deferred tax liabilities     24        
Approved markets | market         50    
Adjustments to carrying value of intangible assets     119        
Adjustments to deferred tax liability     24        
Adjustments to deferred credit     $ 96        
Otezla | Inventories              
Business Acquisition [Line Items]              
Acquired assets, weighted useful life         2 years 6 months    
Otezla | Developed Technology Rights              
Business Acquisition [Line Items]              
Weighted average period of amortization     8 years 6 months        
Otezla | Marketing-Related Rights | Assembled Workforce              
Business Acquisition [Line Items]              
Weighted average period of amortization     5 years        
Nuevolution              
Business Acquisition [Line Items]              
Fair value of liabilities assumed, deferred tax liabilities       $ 22      
Goodwill       26      
Consideration transferred       183      
Fair value of assets acquired and liabilities assumed, net other assets and liabilities       29      
Nuevolution | R & D Technology rights              
Business Acquisition [Line Items]              
Finite-lived Intangible Assets Acquired       $ 150      
Weighted average period of amortization       10 years